Related Experiment Videos
[Should NSAID/corticoids be considered when treating erysipelas?]
R Jaussaud1, E Kaeppler, C Strady
1Service de Médecine Interne et Maladies Infectieuses, CHU Robert-Debré, Reims, France.
Annales De Dermatologie Et De Venereologie
|April 25, 2001
Summary
Non-steroidal anti-inflammatory drugs (NSAID) use in erysipelas treatment remains debated. While potentially reducing inflammation, evidence for NSAID efficacy and safety is limited, warranting caution.
Area of Science:
- Dermatology
- Infectious Diseases
- Pharmacology
Background:
- The use of non-steroidal anti-inflammatory drugs (NSAID) alongside antibiotics for erysipelas is controversial.
- Potential benefits include reduced inflammation and faster symptom relief, but concerns exist regarding invasive streptococcal infections.
Framework:
- Limited evidence exists from controlled trials comparing NSAID efficacy and safety against placebo for erysipelas.
- One study suggested a modest benefit with prednisolone, a corticosteroid, showing a one-day shorter hospital stay.
Implementation:
- The study compared prednisolone treatment with placebo in erysipelas patients.
- Prednisolone-treated patients experienced a shorter median hospital stay and reduced intravenous antibiotic duration.
Implications:
- While not definitively proving a link between NSAID and severe complications, caution is advised when using NSAID for erysipelas.
- Further controlled studies are needed to establish the true efficacy and safety profile of NSAID in erysipelas management.